Department of Pharmaceutical Technology and Biopharmacy, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, H-1111 Budapest, Hungary.
Int J Pharm. 2019 Oct 5;569:118593. doi: 10.1016/j.ijpharm.2019.118593. Epub 2019 Aug 6.
The objectives of this work were to develop meloxicam based amorphous solid dispersion through electrospinning technique and evaluate the effect of the polymeric matrix on the physicochemical properties of the fibers and the downstream processing ability to orodispersible dosage forms. Drug - polymer interactions formed between Eudragit E and meloxicam, confirmed through Raman and 1HNMR spectra, enabled the development of fibers from ethanol, thus allowing an increased production rate compared to PVPk30 where a DMF:THF solvent system was suitable. Microflux dissolution-permeation studies showed a significantly higher diffusion from amorphous solid dispersions compared to crystalline meloxicam. The flux through the membrane was influenced by the polymers only under basic conditions, where the precipitation of Eudragit E limited the complete resolubilization of the active ingredient. This phenomenon was not observed during large volume conventional dissolution testing. The effect of formulation on long term stability could not be highlighted as all products were stable up to 15 months, stored in closed holders at 25 °C ± 2 °C and 50%RH ± 10%. The increased surface area of fibers enabled tablet preparation with low pressures due to favorable bonding between particles during compression. PVPk30 formulation presented higher tabletability and compactability, as higher tensile strength compacts could be prepared. Eudragit E formulation had lower detachment and ejection stress, suggesting a lower sticking tendency during tableting. The presence of HPßCD in PVPk30 formulation offered improved morphological features of the fibers, however no significant effect was observed on dissolution, permeation or mechanical properties. Downstream processing was guided by polymer mechanical properties and solubility, thus PVPk30 fibers could be delivered in the form of orodispersible webs and conventional tablets, whereas Eudragit E fibers as orodispersible tablets.
这项工作的目的是通过静电纺丝技术开发美洛昔康无定形固体分散体,并评估聚合物基质对纤维理化性质和可加工成口腔分散剂型的下游处理能力的影响。通过拉曼和 1HNMR 光谱证实,Eudragit E 与美洛昔康之间形成了药物-聚合物相互作用,使纤维能够从乙醇中发展出来,从而与 PVPk30 相比提高了生产速度,后者适合使用 DMF:THF 溶剂系统。微流量溶解-渗透研究表明,与结晶美洛昔康相比,无定形固体分散体的扩散速度显著提高。只有在碱性条件下,聚合物才会影响通过膜的通量,在这种条件下,Eudragit E 的沉淀会限制活性成分的完全再溶解。在大容量常规溶解试验中没有观察到这种现象。由于所有产品在 25°C±2°C 和 50%RH±10%的密闭支架中储存长达 15 个月时均稳定,因此无法强调制剂对长期稳定性的影响。由于在压缩过程中颗粒之间的有利结合,纤维的表面积增加使得可以用低压力制备片剂。PVPk30 制剂具有更高的可压性和可压缩性,因为可以制备更高拉伸强度的压块。Eudragit E 制剂的分离和弹射应力较低,表明在压片过程中粘性较低。PVPk30 制剂中 HPßCD 的存在提供了纤维更好的形态特征,但对溶解、渗透或机械性能没有观察到显著影响。下游处理由聚合物机械性能和溶解度指导,因此 PVPk30 纤维可以制成口腔分散型纤维网和常规片剂,而 Eudragit E 纤维可以制成口腔分散型片剂。